While these injections have proven beneficial in managing type 2 diabetes and reducing HbA1c levels, they also contribute to cardiovascular health
ADAs 2026 Standards are expanding the relevance of GLP-1-based therapies in diabetes, obesity, and related metabolic care
According to Engel, he started taking Ozempic in 2023, after his doctor prescribed the drug to help him manage his diabetes
slow release of the medication
How is it different from semaglutide and tirzepatide
References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1